keyword
MENU ▼
Read by QxMD icon Read
search

Chemo safety

keyword
https://www.readbyqxmd.com/read/27884204/lateral-pelvic-lymph-node-dissection-after-neoadjuvant-chemo-radiation-for-preoperative-enlarged-lateral-nodes-in-advanced-low-rectal-cancer-study-protocol-for-a-randomized-controlled-trial
#1
Mingtian Wei, Qingbin Wu, Chuanwen Fan, Yan Li, Xiangzheng Chen, Zongguang Zhou, Junhong Han, Ziqiang Wang
BACKGROUND: Lateral lymph node (LLN) metastasis is a major cause of local recurrence of advanced rectal cancer. Although there is much controversy between Western and Eastern countries on whether lateral pelvic lymph node dissection (LLND) or neoadjuvant chemo-radiation (nCRT) is preferable for the treatment of LLN metastases, existing retrospective cohorts mainly focus on all middle/low advanced rectal cancer patients, not the specific individuals with suspicion of LLN metastases. The aim of this trial is to assess the efficacy and safety of LLND for rectal cancer patients with suspicion of LLN metastases...
November 25, 2016: Trials
https://www.readbyqxmd.com/read/27882237/autologous-tumor-immunizing-devascularization-of-an-invasive-colorectal-cancer-a-case-report-and-literature-review
#2
Pavel Vašek, Josef Krajnik, David J Kopsky, Vladimir Kalina, Marek Frydrych
Colorectal cancer is the third most common cancer. Approximately 20% of patients have at the time of presentation metastasized colorectal cancer, which is incurable in ~80% of cases. The present case report describes a typical case diagnosed with an advanced invasive colorectal adenocarcinoma, with two suspect hypodense lesions in the liver, as revealed by sonography. Judged inoperable for a curative outcome by radical resection, the patient was treated with a novel surgical technique based on stimulating the immune system, termed 'autologous tumor immunizing devascularization' (ATID)...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27878354/randomized-phase-ii-study-of-cetuximab-versus-irinotecan-and-cetuximab-in-patients-with-chemo-refractory-kras-codon-g13d-metastatic-colorectal-cancer-g13d-study
#3
Masato Nakamura, Toru Aoyama, Keiichiro Ishibashi, Akihito Tsuji, Yasutaka Takinishi, Yoshiaki Shindo, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
PURPOSE: This study investigated the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory mCRC with KRAS G13D mutation. PATIENTS AND METHODS: An assessment of the efficacy and safety of cetuximab-based treatment was performed in an observation-enriched randomized controlled study comparing the cetuximab alone group (Cet group) and the combination of cetuximab and irinotecan group (CetI group) for KRAS G13D-mutated mCRC in Japan...
November 22, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27868581/2016-updated-american-society-of-clinical-oncology-oncology-nursing-society-chemotherapy-administration-safety-standards-including-standards-for-pediatric-oncology
#4
Michael N Neuss, Terry R Gilmore, Kristin M Belderson, Amy L Billett, Tara Conti-Kalchik, Brittany E Harvey, Carolyn Hendricks, Kristine B LeFebvre, Pamela B Mangu, Kristen McNiff, MiKaela Olsen, Lisa Schulmeister, Ann Von Gehr, Martha Polovich
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards...
November 21, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27855898/isolation-and-chemoenzymatic-treatment-of-glycoalkaloids-from-green-sprouting-and-rotting-solanum-tuberosum-potatoes-for-solanidine-recovery
#5
Grokoré Yvonne Koffi, Magali Remaud-Simeon, Ahipo Edmond Due, Didier Combes
The estimation of glycoalkaloids in the flesh of different types of decayed potatoes was evaluated. The results showed that turned green and also sprouting or rotting potato flesh contain high amounts of toxic solanine and chaconine, exceeding by 2-5-fold the recommended limit, and ranging from 2578±86mg/kg to 5063±230mg/kg of dry weight potato flesh. For safety consideration, these decayed potatoes should be systematically set aside. To avoid a net economic loss and encourage the removal of this hazardous food, a recycling process was investigated to generate added-value compounds from the toxic glycoalkaloids...
April 1, 2017: Food Chemistry
https://www.readbyqxmd.com/read/27849340/intra-arterial-cetuximab-for-the-treatment-of-recurrent-unresectable-head-and-neck-squamous-cell-carcinoma-%C3%A2
#6
Tristan Tham, Timothy G White, Shamik Chakraborty, Rohan R Lall, Rafael Ortiz, David J Langer, Deborah Shatzkes, Christopher G Filippi, Dennis Kraus, John A Boockvar, Peter D Costantino
IMPORTANCE: Management of recurrent head and neck squamous cell carcinoma is a common and challenging clinical problem in head and neck oncology. OBJECTIVE: Here we present the first reported case of super-selective intra-arterial (SSIA) microcatheter based local delivery of cetuximab for head and neck cancer. This technical report describes the techniques used to deliver the SSIA dose of cetuximab, as well as the patient outcome. DESIGN: This technical report is part of an ongoing Phase I Clinical Trial...
November 2016: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/27796157/management-of-elderly-and-unfit-patients-with-chronic-lymphocytic-leukemia
#7
Francesca R Mauro, Adriano Salaroli, Maria D Caputo, Gioia Colafigli, Luigi Petrucci, Melissa Campanelli, Antonietta Ferretti, Anna R Guarini, Robin Foà
About 75% of patients with chronic lymphocytic leukemia (CLL) are more than 65 years at the time of diagnosis. Treatment of the elderly remains complicated due to multiple factors, such as comorbidities, decline in functional reserve and fitness. Since chronological age by itself cannot properly predict life expectancy and treatment tolerance, an accurate assessment of the fitness status is of crucial importance for an optimal treatment choice. Areas covered: This review will discuss the most relevant aspects concerning the issues experienced in the management of elderly/unfit patients with CLL...
December 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27790867/adjuvant-treatment-combining-cellular-immunotherapy-with-chemotherapy-improves-the-clinical-outcome-of-patients-with-stage-ii-iii-gastric-cancer
#8
Yizhuo Wang, Chang Wang, Huijie Xiao, Chao Niu, Haitao Wu, Haofan Jin, Cheng Yao, Hua He, Huimin Tian, Fujun Han, Dan Li, Wei Han, Jianting Xu, Jingtao Chen, Jiuwei Cui, Wei Li
Postsurgical relapse remains a common issue for resectable gastric cancer (GC). Here, we investigated the efficacy and safety of an adjuvant treatment combining chemotherapy with cellular immunotherapy (CIT) using autologous natural killer cells, γδT cells, and cytokine-induced killer cells in the treatment of stage II/III GC. A pilot prospective cohort study was conducted in 169 patients with stage II/III GC who had undergone gastrectomy with D2 lymph node dissection. Patients were assigned into two groups according to the patient choice of treatment, including chemotherapy alone (chemo) or chemotherapy combined with CIT (chemo/CIT)...
October 27, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27789196/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for-patients-with-oligometastatic-non-small-cell-lung-cancer-without-progression-after-first-line-systemic-therapy-a-multicentre-randomised-controlled-phase-2-study
#9
Daniel R Gomez, George R Blumenschein, J Jack Lee, Mike Hernandez, Rong Ye, D Ross Camidge, Robert C Doebele, Ferdinandos Skoulidis, Laurie E Gaspar, Don L Gibbons, Jose A Karam, Brian D Kavanagh, Chad Tang, Ritsuko Komaki, Alexander V Louie, David A Palma, Anne S Tsao, Boris Sepesi, William N William, Jianjun Zhang, Qiuling Shi, Xin Shelley Wang, Stephen G Swisher, John V Heymach
BACKGROUND: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative therapy for patients with oligometastatic NSCLC is unknown. We aimed to assess the effect of local consolidative therapy on progression-free survival. METHODS: In this multicentre, randomised, controlled, phase 2 study, eligible patients from three hospitals had histological confirmation of stage IV NSCLC, three or fewer metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group performance status score of 2 or less, had received standard first-line systemic therapy, and had no disease progression before randomisation...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27784174/cardiac-safety-of-systemic-therapy-in-breast-cancer-patients-with-high-risk-of-atherosclerosis-complications
#10
Arthur Matyszewski, Anna M Czarnecka, Paweł Stachowiak, Marta Nowakowska, Zdzisława Kornacewicz-Jach, Jarosław D Kasprzak, Cezary Szczylik
AIM: This study was designed to verify the efficacy of breast cancer treatment and its cardiac toxicity in population with significant cardiac comorbidities. MATERIALS & METHODS: Prospective observational study was conducted in 48 patients. RESULTS: The increase and dependence of echocardiographic parameter early/late were observed on hemoglobin level in all patients, and white blood cells and cholesterol in patients with diabetic were reported...
October 27, 2016: Future Oncology
https://www.readbyqxmd.com/read/27782084/measles-to-the-rescue-a-review-of-oncolytic-measles-virus
#11
REVIEW
Sarah Aref, Katharine Bailey, Adele Fielding
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis...
October 22, 2016: Viruses
https://www.readbyqxmd.com/read/27779929/vector-control-in-developing-countries-challenges-and-solutions
#12
Claire S Allardyce, Paul J Dyson, Michael Grätzel
Undoubtedly, reducing vector populations or their interactions with hosts below a critical level is a practical and proven method of disease control. Introduction of insecticide-treated bed nets has significantly reduced malaria in some parts of the world. However, for many reasons, implementation of such strategies is challenging and the protection offered by particular products limited: bed nets are only effective during sleep. Other methods have been launched, but low customer appeal, high cost, low specificity, and lack of sustainability and effectiveness are often reasons for failure...
October 2016: Chimia
https://www.readbyqxmd.com/read/27760950/-development-of-peptide-vaccines-for-triple-negative-breast-cancer-treatment
#13
Uhi Toh, Shuko Saku, Mina Okabe, Nobutaka Iwakuma, Yuko Kimitsuki, Momoko Akashi, Etsuyo Ogo, Akira Yamada, Shigeki Shichijo, Kyogo Itoh, Yoshito Akagi
Our previous phase II clinical trial showed that therapeutically selected personalized peptide vaccines(PPVs)were effective at boosting anticancer immunity; the immune response after PPV was associated with a clinical outcome as a prognostic factor for metastatic breast cancer(mBC). We conducted an early phase II study to evaluate the safety and efficacy of a new regimen using multiple peptide vaccines(KRM-19)for patients with metastatictriple -negative breast cancer. KRM-19 consisted of 19 mixed peptides chosen from the previously reported 31 PPVs according to their anti-tumor immunologiceffec ts and safety profiles for patients with mBC...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27737598/the-safety-of-anti-pd-1-therapeutics-for-the-treatment-of-melanoma
#14
Egle Ramelyte, Sabrina A Schindler, Reinhard Dummer
Introduction The introduction of immunotherapies into clinical practice has substantially improved the prognosis of metastatic melanoma patients as well as patients suffering from other cancers. The two FDA-approved checkpoint inhibitors against PD-1 (nivolumab and pembrolizumab) have been shown to significantly improve patient survival while being less toxic than previous treatment options. Areas covered The current scientific literature on safety and adverse events (AEs) related to anti-PD-1 therapies has been investigated with special attention to case reports and to the latest results announced at the major clinical cancer and melanoma meetings, including ASCO (American Society of Clinical Oncology), ESMO (European Society of medical Oncology) and EADO (European Association of Dermato-Oncology) annual meetings...
October 13, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27725524/phase-i-ii-study-of-temozolomide-plus-nimustine-chemotherapy-for-recurrent-malignant-gliomas-kyoto-neuro-oncology-group
#15
Tomokazu Aoki, Yoshiki Arakawa, Tetsuya Ueba, Masashi Oda, Namiko Nishida, Yukinori Akiyama, Tetsuya Tsukahara, Koichi Iwasaki, Nobuhiro Mikuni, Susumu Miyamoto
The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(2)/day) (Day 1-5) plus various doses of ACNU (30, 35, 40, 45 mg/m(2)/day) (Day 15) per 4 weeks was defined on a standard 3 + 3 design. In phase II, these therapeutic activity and safety of this regimen were evaluated...
October 11, 2016: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/27697601/overcoming-cisplatin-resistance-in-non-small-cell-lung-cancer-with-mad2-silencing-sirna-delivered-systemically-using-egfr-targeted-chitosan-nanoparticles
#16
Ana Vanessa Nascimento, Amit Singh, Hassan Bousbaa, Domingos Ferreira, Bruno Sarmento, Mansoor M Amiji
: Efficiency of chemotherapy is often limited by low therapeutic index of the drug as well as emergence of inherent and acquired drug resistance in cancer cells. As a common strategy to overcome drug resistance, higher doses of chemo-agents are administered. However, adverse side effects are usually increased as a consequence. A potentially effective approach is to combine chemotherapy with other therapeutic strategies such as small interfering RNAs (siRNAs) that allow the use of lower yet efficient doses of the anticancer drugs...
January 1, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/27633405/development-of-ayurveda-tradition-to-trend
#17
Pulok K Mukherjee, Ranjit K Harwansh, Shiv Bahadur, Subhadip Banerjee, Amit Kar, Joydeb Chanda, Sayan Biswas, Sk Milan Ahmmed, C K Katiyar
ETHNOPHARMACOLOGICAL RELEVANCE: Ayurveda entails a scientific tradition of harmonious living and its origin can be traced from ancient knowledge contained in Rigveda and Atharvaveda. Ayurveda is a traditional healthcare system of Indian medicine since time immortal. Several Ayurvedic medicines have been exploiting for treatment and management of various diseases in human beings. The several drugs have been developed and practiced from Ayurveda since ancient time to modern practice as 'tradition to trend'...
September 12, 2016: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/27612171/the-impact-of-diffusion-weighted-mri-on-the-definition-of-gross-tumor-volume-in-radiotherapy-of-non-small-cell-lung-cancer
#18
Jochen Fleckenstein, Michael Jelden, Stephanie Kremp, Philippe Jagoda, Jonas Stroeder, Fadi Khreish, Samer Ezziddin, Arno Buecker, Christian Rübe, Guenther K Schneider
OBJECTIVE: The study was designed to evaluate diffusion-weighted magnetic resonance imaging (DWI) vs. PET-CT of the thorax in the determination of gross tumor volume (GTV) in radiotherapy planning of non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligible patients with NSCLC who were supposed to receive definitive radio(chemo)therapy were prospectively recruited. For MRI, a respiratory gated T2-weighted sequence in axial orientation and non-gated DWI (b = 0, 800, 1,400 and apparent diffusion coefficient map [ADC]) were acquired on a 1...
2016: PloS One
https://www.readbyqxmd.com/read/27604091/metformin-and-anti-cancer-therapeutics-hopes-for-a-more-enhanced-armamentarium-against-human-neoplasias
#19
Maria-Ioanna Christodoulou, Andreas Scorilas
Metformin, a natural product from Galga officinalis, is an oral drug, now in the forefront of the therapeutic management of type-2 diabetes mellitus. A series of clinical observations of the last decades, support that metformin may contribute to lowering the risk of cancer development in diabetic patients, and also to improvement of response-to-therapy and survival in individuals with certain types of malignancies. Moreover, several preclinical in-vitro and in-vivo data indicate that metformin indeed exerts anti-proliferative capacities upon tumor cells mediated through a variety of mechanisms...
September 7, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27586524/perspectives-on-making-big-data-analytics-work-for-oncology
#20
Issam El Naqa
Oncology, with its unique combination of clinical, physical, technological, and biological data provides an ideal case study for applying big data analytics to improve cancer treatment safety and outcomes. An oncology treatment course such as chemoradiotherapy can generate a large pool of information carrying the 5Vs hallmarks of big data. This data is comprised of a heterogeneous mixture of patient demographics, radiation/chemo dosimetry, multimodality imaging features, and biological markers generated over a treatment period that can span few days to several weeks...
December 1, 2016: Methods: a Companion to Methods in Enzymology
keyword
keyword
104142
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"